The clinical challenge is the current lack of less invasive, bone-sparing surgical procedures that both deal with the underlying osteochondral disease and postpone the eventual need for total joint replacement. Unfortunately for both surgeons and their patients, no such options exist. Dr. Thomas Vail, Chair of Orthopaedic Surgery, UCSF, and member of Cytex’s Clinical Advisory Board, states “Orthopaedic surgeons have been waiting for cartilage resurfacing technology for years. If efficacy can be shown, this technology will rapidly be adopted.” For these reasons, Cytex believes that a product that repairs only the damaged tissue in the articular joint could be a more appropriate option than the current standard of care of total joint replacement.